Completed PHASE4 INTERVENTIONAL 2-arm NCT00512057

APEX Study: Effects of Allopurinol on Coronary and Peripheral Endothelial Function in Patients With Cardiac Syndrome X (APEX)

Sponsor: University of Dundee

Updated 5 times since 2017 Last updated: Jun 25, 2010 Started: Jun 30, 2008 Primary completion: Jun 30, 2010 Completion: Jun 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00512057, this PHASE4 trial focuses on Syndrome X and remains completed. Sponsored by University of Dundee, it has been updated 5 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Dundee

Data source: University of Dundee

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dundee, United Kingdom